Prospective study for correlation between disease progression and detection of T790M in plasma DNA using MBP-QP method in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

Prospective study for correlation between disease progression and detection of T790M in plasma DNA using MBP-QP method in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors - Prospective study for correlation between disease progression and T790M detection in plasma DNA in non-small cell lung cancer (HASAT study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005131

Enrollment

Registered

2011-03-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Non-small cell lung cancer patients with EGFR activating mutations such as exon 19 deletion and L858R. 2. Non-small cell lung cancer patients with lesions which can be evaluated by RECIST (Version 1.1). 3. Non-small cell lung cancer patients with written consent.

Exclusion criteria

Exclusion criteria: 1. Non-small cell lung cancer patients with EGFR mutations which is related with acquired resistance such as T790M. 2. Non-small cell lung cancer patients who is not appropriated for the study determined by physician in charge.

Design outcomes

Primary

Measure	Time frame
The population of patients with presence of T790M in plasma DNA among those who acquired resistance to EGFR-TKI is calculated.	—

Secondary

Measure	Time frame
The concordance of T790M in plasma DNA and those in cancer tissues or effusions are evaluated. The serial analysis of T790M in plasma DNA and anti-tumor effect of EGFR-TKI are also examined.	—

Countries

Japan

Contacts

Public ContactNaoko Aragane

Hanshin-Saga Collaborative Cancer Study Group Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga Univ.

sueokan@cc.saga-u.ac.jp0952-34-2369

Outcome results